Apyx Medical (APYX) Stock Price, News & Analysis

Company Overview

Apyx Medical Corporation (NASDAQ: APYX) is a medical technology company that develops, manufactures and markets advanced energy systems for use in surgical and aesthetic procedures. The company’s products are based primarily on its proprietary Helium Plasma technology, which combines helium gas and radiofrequency energy to deliver controlled thermal effects to soft tissue.

Its principal product platform is Renuvion, a system designed for use by physicians in soft-tissue procedures. The platform includes generators, handpieces and related accessories intended to support tissue coagulation, cutting, dissection and contraction in various surgical and aesthetic applications. Apyx Medical also offers Plasma/RF products for hospital and ambulatory surgical settings.

The company was formerly known as Bovie Medical Corporation and adopted the Apyx Medical name in 2018 as it focused more closely on its advanced energy technology portfolio. Apyx Medical serves customers in the United States and international markets through a combination of direct sales and distribution relationships. The company is headquartered in Clearwater, Florida, and is led by President and Chief Executive Officer Charlie Goodwin.

Key Stats

• Today's Range: $2.38 to $2.62
• 50-Day Range: $2.36 to $4.28
• 52-Week Range: $2.32 to $5.08
• Volume: 103,518 shs
• Average Volume: 162,392 shs
• Market Capitalization: $109.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Moderate Buy

Apyx Medical Stock Analysis - MarketRank™

Apyx Medical scored higher than 56% of companies evaluated by MarketBeat, and ranked 410th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Apyx Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Apyx Medical has a consensus price target of $6.50, representing about 151.0% upside from its current price of $2.59.

Amount of Analyst Coverage

Apyx Medical has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Apyx Medical are expected to remain at ($0.25) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Apyx Medical is -12.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Apyx Medical is -12.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Apyx Medical has a P/B Ratio of 6.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.58% of the float of Apyx Medical has been sold short.

Short Interest Ratio / Days to Cover

Apyx Medical has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apyx Medical has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apyx Medical does not currently pay a dividend.

Dividend Growth

Apyx Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Apyx Medical this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Apyx Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.90% of the stock of Apyx Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.33% of the stock of Apyx Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:APYX
• CIK: 719135
• Web: www.apyxmedical.com
• Phone: (727) 384-2323
• Fax: 800-323-1640
• Employees: 205
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Apyx Medical: $6.50
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +151.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.21 million
• Net Margins: -14.78%
• Pretax Margin: -13.65%
• Return on Equity: -76.60%
• Return on Assets: -13.91%

Debt

• Debt-to-Equity Ratio: 3.19
• Current Ratio: 5.68
• Quick Ratio: 4.53

Sales & Book Value

• Annual Sales: $52.84 million
• Price / Sales: 2.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 6.64

Miscellaneous

• Outstanding Shares: 42,120,000
• Free Float: 35,426,000
• Market Cap: $109.09 million
• Optionable: Optionable
• Beta: 1.45